Nirsevimab is an antibody targeting the respiratory syncytial virus (RSV). Available in France since September 2023, it is indicated in neonates and infants for the prevention of bronchiolitis caused....
MASH, formerly known as NASH, is a serious chronic liver disease that affects around 4-6% of the world's adult population. A new study reveals that, contrary to what was....
